TEM logo

Tempus AI

TEM · What the business does, what can go wrong, and how options sellers approach it

What it does

Tempus AI is a healthcare technology company focused on precision medicine. It runs genomic and other laboratory tests, mainly in cancer care, and pairs the results with clinical data. It then applies software and machine learning to that data.

The company has two broad sides. One is diagnostics, where it provides testing to physicians and patients. The other is data and software, where it licenses de-identified datasets and analytical tools to drug developers and other life sciences customers.

How it makes money

Diagnostics revenue comes from tests ordered by clinicians and paid for by insurers, government programs, hospitals or patients. Payment depends heavily on coverage and reimbursement decisions.

Data and services revenue comes from pharmaceutical and biotech companies. They pay for access to datasets, for help finding patients for studies, and for tools that support drug discovery and development. These deals are often contract-based and can vary in size and timing.

Why investors own it

Investors are generally drawn to the idea that a large, well-organized library of clinical and molecular data can become more valuable as it grows, since testing brings in more data that can support new products and partnerships. Others see a way to own the overlap of healthcare, diagnostics and AI in a single company.

What can go wrong

  • Reimbursement for lab tests can change, and payers may deny or reduce coverage.
  • The company has a history of operating losses, so it may need outside funding if growth falls short.
  • Pharma customers can delay or cut data and research spending.
  • Rules on patient privacy, data use and lab-developed tests may tighten.
  • Competition comes from established diagnostics firms and other health data companies.
  • Expectations for AI may run ahead of results.

What to watch

  • Diagnostics test volumes
  • Data and services revenue growth
  • Progress toward profitability and free cash flow
  • Reimbursement and coverage decisions
  • Equity or debt issuance

Options income angle

Options on TEM are generally actively traded, though liquidity and bid-ask spreads can vary by expiration and strike.

Implied volatility tends to rise around earnings, reimbursement news and shifts in sentiment toward AI and healthcare technology. Because the stock can move sharply, implied volatility has tended to be elevated compared with many large, established companies.

One caution for anyone selling premium: a sharp move after earnings or a regulatory headline can quickly overwhelm the income collected, and a short put can lead to owning the shares after a steep drop.

Follow TEM in Kortex

The Kortex app shows TEM's price, options chain and IV rank, and answers your questions from live market data and SEC filings.

Free to download.

Learn the strategies

More stock briefs

For education only, not financial advice. Options involve risk and are not suitable for every investor.